Log in

Relevant bibliographies by topics / Warfarin / Journal articles

To see the other types of publications on this topic, follow the link: Warfarin.

Journal articles on the topic 'Warfarin'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Warfarin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Alsancak, Yakup, Serkan Sivri, Telat Keleş, Tahir Durmaz, and Engin Bozkurt. "A rare complication of warfarin: late onset warfarin induced skin necrosis." Türk Aile Hekimliği Dergisi 21, no. 1 (2017): 41–43. http://dx.doi.org/10.15511/tahd.17.00141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Li, Qiang, Wen-yue Yang, Ling-ling Qu, Huan-Yang Qi, Yun Huang, and Zheng Zhang. "Interaction of Warfarin with Human Serum Albumin and Effect of Ferulic Acid on the Binding." Journal of Spectroscopy 2014 (2014): 1–7. http://dx.doi.org/10.1155/2014/834501.

Full text

Abstract:

Angelica sinensis(Oliv.) Diels combined treatment with warfarin would increase the risk of bleeding. Ferulic acid is an abundant hydroxycinnamic acid inA. sinensisand warfarin is the most widely used oral anticoagulant. The studies on supermolecular interaction of warfarin with human serum albumin (HSA) and the influence of ferulic acid on the binding would contribute to the understanding of the metabolic processes of warfarin and the effect of ferulic acid. We focus on investigating the effect of warfarin on fluorescence spectrum of human serum albumin (HSA), fluorescence quenching mechanism,

APA, Harvard, Vancouver, ISO, and other styles

3

Thompson, Dennis F., Marsha A. Raebel, Elizabeth K. Hussey, and George E. Dukes. "Do All Histamine2-Antagonists Cause a Warfarin Drug Interaction?" DICP 23, no. 9 (1989): 675–79. http://dx.doi.org/10.1177/106002808902300911.

Full text

Abstract:

Cimetidine, the first marketed histamine2-receptor antagonist, has been shown to decrease the clearance of warfarin consistently through inhibition of cytochrome P-450 metabolism. The clinical significance of this drug–drug interaction has been questioned due to: (1) the lowering of the warfarin therapeutic range, (2) the lowering of the total daily therapeutic cimetidine dosage, (3) the advent of once-daily cimetidine dosing, and (4) the demonstration that the clearance of the less active warfarin R-enantiomer is decreased to a greater extent than the more active S-enantiomer. Ranitidine has

APA, Harvard, Vancouver, ISO, and other styles

4

Jaffer, Amir, Jason Hurbanek, Nariman Morra, and Daniel Brotman. "Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty." Thrombosis and Haemostasis 92, no. 11 (2004): 1012–17. http://dx.doi.org/10.1160/th04-04-0204.

Full text

Abstract:

SummaryMany orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty. Since warfarin’s antithrombotic effects are delayed, we hypothesized that early VTE (occurring within 5 days post-operatively) would be more common in arthroplasty patients receiving warfarin monotherapy compared to those receiving enoxaparin. We performed a secondary analysis of a case-control study examining risk factors for post-operative thrombosis in postmenopausal women. We defined cases as patients who were diagnosed with thrombosis within 5 days of surgery. Controls

APA, Harvard, Vancouver, ISO, and other styles

5

Meeks, Mimi L., Kenneth W. Mahaffey, and Michael D. Katz. "Danazol Increases the Anticoagulant Effect of Warfarin." Annals of Pharmacotherapy 26, no. 5 (1992): 641–42. http://dx.doi.org/10.1177/106002809202600506.

Full text

Abstract:

OBJECTIVE: To report two cases demonstrating an interaction between danazol and warfarin, resulting in the potentiation of warfarin's effect and bleeding complications. DATA SOURCES: Case reports, review articles, and studies identified by MEDLINE. STUDY SELECTION: All published English-language reports involving danazol and warfarin interactions were reviewed. DATA SYNTHESIS: Danazol, a synthetic testosterone derivative, is used in the treatment of endometriosis, fibrocystic breast disease, menorrhagia protein C deficiency, and hemophilia. We describe two cases including an interaction betwee

APA, Harvard, Vancouver, ISO, and other styles

6

Milligan, Paul E., Gerald A. Banet, Amy D. Waterman, Susan K. Gatchel, and Brian F. Gage. "Substitution of Generic Warfarin for Coumadin in an HMO Setting." Annals of Pharmacotherapy 36, no. 5 (2002): 764–68. http://dx.doi.org/10.1345/aph.1a327.

Full text

Abstract:

BACKGROUND: Substitution of generic warfarin for Coumadin presents safety concerns due to warfarin's narrow therapeutic index and because a prior generic formulation was removed from the US market after it was associated with adverse events. OBJECTIVE: To determine whether a health maintenance organization (HMO) can add generic warfarin to its formulary without adversely affecting warfarin management or increasing adverse events. DESIGN: In a prospective, observational study, an HMO that formerly dispensed only Coumadin added a generic warfarin preparation (Barr Laboratories, Pomona, NY) to it

APA, Harvard, Vancouver, ISO, and other styles

7

Jones, Cade B., and Susan E. Fugate. "Levofloxacin and Warfarin Interaction." Annals of Pharmacotherapy 36, no. 10 (2002): 1554–57. http://dx.doi.org/10.1345/aph.1c074.

Full text

Abstract:

OBJECTIVE: To report 4 cases of hypoprothrombotic response resulting from addition of levofloxacin therapy to chronic warfarin therapy and to review related literature to support or refute a warfarin—levofloxacin interaction. CASE SUMMARY: Four patients, 34–81 years old, were prescribed levofloxacin concomitantly with stable warfarin therapy. Three patients had a target international normalized ratio (INR) range of 2.0–3.0 and experienced an increase in INR to 3.5, 8.12, and 11.5 on days 11, 5, and 4 of a 10-day course of levofloxacin, respectively. The fourth patient experienced minor bleedin

APA, Harvard, Vancouver, ISO, and other styles

8

Umashankar, Niroja, and Binju Mercy Oommen. "The role of warfarin in anticoagulation therapy: Current insight’s and clinical perspectives." Indian Journal of Pharmacy and Pharmacology 11, no. 4 (2024): 178–84. https://doi.org/10.18231/j.ijpp.2024.031.

Full text

Abstract:

Warfarin, a widely used oral anticoagulant and vitamin K antagonist, plays a critical role in the prevention and treatment of venous thrombosis and thromboembolic complications. This review explores the pharmacological properties, pharmacokinetics, pharmacodynamics, therapeutic monitoring, and drug-food interactions of warfarin. By inhibiting vitamin K-dependent clotting factors, warfarin induces a controlled anticoagulation state. However, its narrow therapeutic index presents challenges in achieving and maintaining optimal dosing. Regular monitoring of the International Normalized Ratio (INR

APA, Harvard, Vancouver, ISO, and other styles

9

Casserly, Elizabeth A., Sara E. Rogers, and Sidney V. Keisner. "Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient." Journal of Oncology Pharmacy Practice 23, no. 1 (2016): 68–70. http://dx.doi.org/10.1177/1078155215609979.

Full text

Abstract:

Enzalutamide is an androgen receptor antagonist used for the treatment of metastatic castration-resistant prostate cancer. Enzalutamide is classified as a strong cytochrome P450 3A4 inducer, a moderate 2C9 and 2C19 inducer, and a time-dependent inducer of 1A2. Warfarin’s more potent enantiomer is primarily metabolized by cytochrome P450 2C9 and has a narrow therapeutic window. Enzalutamide is thought to decrease therapeutic warfarin concentrations per pharmacokinetic studies performed during drug development. This case report describes a 59–year-old man undergoing treatment with enzalutamide f

APA, Harvard, Vancouver, ISO, and other styles

10

Kim, Karissa Y., and Michael A. Mancano. "Fenofibrate Potentiates Warfarin Effects." Annals of Pharmacotherapy 37, no. 2 (2003): 212–15. http://dx.doi.org/10.1177/106002800303700210.

Full text

Abstract:

OBJECTIVE: To describe 2 patients in whom the initiation of fenofibrate potentiated warfarin's anticoagulant effects. CASE SUMMARY: A 71-year-old white woman and an 80-year-old white woman with multiple medical conditions were both stabilized on long-term warfarin therapy. During the course of anticoagulation, both patients were prescribed fenofibrate and experienced threefold and twofold increases in international normalized ratio (INR), respectively, requiring total weekly warfarin dosage reductions of 30–40%. Before starting fenofibrate therapy, both patients' coagulation values were within

APA, Harvard, Vancouver, ISO, and other styles

11

Ruiz-Ruiz, Francisco J. "Warfarin or Not Warfarin?" Annals of Internal Medicine 142, no. 8 (2005): 676. http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Fang, Margaret C., and Daniel E. Singer. "Warfarin or Not Warfarin?" Annals of Internal Medicine 142, no. 8 (2005): 676. http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

King, Cynthia A., Kathleen M. Babcock, Rhianna J. Godios, and Benjamin S. King. "Significant drug–drug interaction between warfarin and nafcillin." Therapeutic Advances in Drug Safety 9, no. 11 (2018): 667–71. http://dx.doi.org/10.1177/2042098618796186.

Full text

Abstract:

Nafcillin, a beta-lactam semisynthetic penicillin, is highly resistant to penicillinase and is similar to other penicillins except that it is primarily metabolized in the liver. It is believed that nafcillin causes CYP3A4 enzyme induction which decreases warfarin’s half-life. The onset of CYP3A4 induction by nafcillin occurs within the first 7 days, but maximal effects may take up to 2 weeks. Once nafcillin is discontinued, the effects persist for several weeks. A 79-year-old male with a history of atrial fibrillation and a 53-year-old male with a history of recurrent venous thromboembolism re

APA, Harvard, Vancouver, ISO, and other styles

14

Ahmad, Yousif, and Gregory Y. H. Lip. "Stroke Prevention in Atrial Fibrillation: Where are We Now?" Clinical Medicine Insights: Cardiology 6 (January 2012): CMC.S8976. http://dx.doi.org/10.4137/cmc.s8976.

Full text

Abstract:

Atrial fibrillation is the commonest arrhythmia worldwide and is a growing problem. AF is responsible for 25% of all strokes, and these patients suffer greater mortality and disability. Warfarin has traditionally been the only successful therapy for stroke prevention, but its limitations have resulted in underutilisation. Major progress has been made in AF research, leading to improved management strategies. Better risk stratification permits identification of truly low-risk patients who do not require anticoagulation and we are able to simplify ourevaluation of a patient's bleeding risk. The

APA, Harvard, Vancouver, ISO, and other styles

15

Park, Soohyun, and Insil Jang. "Factors Affecting Medication Adherence in Patients with Mechanical Heart Valves Taking Warfarin: The Role of Knowledge on Warfarin, Medication Belief, Depression, and Self-Efficacy." International Journal of Environmental Research and Public Health 18, no. 10 (2021): 5214. http://dx.doi.org/10.3390/ijerph18105214.

Full text

Abstract:

Non-adherence is highlighted as one of the main contributors to the occurrence of adverse events and negative clinical outcomes in patients treated with warfarin. The aim was to examine knowledge on warfarin, medication belief, depression, and self-efficacy as factors influencing medication adherence for anticoagulation control. This was a cross-sectional study. The participants in this study were patients who visited an outpatient clinic of cardiovascular surgery to administer anticoagulants after mechanical valve replacement surgery at a tertiary hospital in Seoul. Responses of 154 participa

APA, Harvard, Vancouver, ISO, and other styles

16

Abdulaziz, Alamri, Bawazeer Ahmad, Almotiri Tariq, et al. "Warfarin: An Anticoagulant Therapy Review." International Journal of Innovative Research in Engineering & Multidisciplinary Physical Sciences 4, no. 4 (2016): 1–4. https://doi.org/10.5281/zenodo.13485767.

Full text

Abstract:

Warfarin, a vitamin K antagonist (VKA), is one of the most commonly prescribed oral anticoagulant medications worldwide (1). It has been used clinically for over 60 years and remains an important therapeutic option for the prevention and treatment of thromboembolic disorders. Warfarin's mechanism of action involves the inhibition of vitamin K epoxide reductase, an enzyme crucial for the activation of vitamin K-dependent clotting factors II, VII, IX, and X (2). This disruption in the coagulation cascade leads to a reduction in the body's ability to form blood clots. The therapeutic use of warfa

APA, Harvard, Vancouver, ISO, and other styles

17

Abdulaziz, Alamri, Bawazeer Ahmad, Almotiri Tariq, et al. "Warfarin: An Anticoagulant Therapy Review." International Journal of Innovative Research in Engineering & Multidisciplinary Physical Sciences 4, no. 4 (2016): 1–4. https://doi.org/10.5281/zenodo.13485767.

Full text

Abstract:

Warfarin, a vitamin K antagonist (VKA), is one of the most commonly prescribed oral anticoagulant medications worldwide (1). It has been used clinically for over 60 years and remains an important therapeutic option for the prevention and treatment of thromboembolic disorders. Warfarin's mechanism of action involves the inhibition of vitamin K epoxide reductase, an enzyme crucial for the activation of vitamin K-dependent clotting factors II, VII, IX, and X (2). This disruption in the coagulation cascade leads to a reduction in the body's ability to form blood clots. The therapeutic use of warfa

APA, Harvard, Vancouver, ISO, and other styles

18

Abdulaziz, Alamri, Bawazeer Ahmad, Almotiri Tariq, et al. "Warfarin: An Anticoagulant Therapy Review." International Journal of Innovative Research in Engineering & Multidisciplinary Physical Sciences 4, no. 4 (2016): 1–4. https://doi.org/10.5281/zenodo.13485767.

Full text

Abstract:

Warfarin, a vitamin K antagonist (VKA), is one of the most commonly prescribed oral anticoagulant medications worldwide (1). It has been used clinically for over 60 years and remains an important therapeutic option for the prevention and treatment of thromboembolic disorders. Warfarin's mechanism of action involves the inhibition of vitamin K epoxide reductase, an enzyme crucial for the activation of vitamin K-dependent clotting factors II, VII, IX, and X (2). This disruption in the coagulation cascade leads to a reduction in the body's ability to form blood clots. The therapeutic use of warfa

APA, Harvard, Vancouver, ISO, and other styles

19

Abdulaziz, Alamri, Bawazeer Ahmad, Almotiri Tariq, et al. "Warfarin: An Anticoagulant Therapy Review." International Journal of Innovative Research in Engineering & Multidisciplinary Physical Sciences 4, no. 4 (2016): 1–4. https://doi.org/10.5281/zenodo.13485767.

Full text

Abstract:

Warfarin, a vitamin K antagonist (VKA), is one of the most commonly prescribed oral anticoagulant medications worldwide (1). It has been used clinically for over 60 years and remains an important therapeutic option for the prevention and treatment of thromboembolic disorders. Warfarin's mechanism of action involves the inhibition of vitamin K epoxide reductase, an enzyme crucial for the activation of vitamin K-dependent clotting factors II, VII, IX, and X (2). This disruption in the coagulation cascade leads to a reduction in the body's ability to form blood clots. The therapeutic use of warfa

APA, Harvard, Vancouver, ISO, and other styles

20

Sahinkus, Salih. "In-Hospital Clinical Ooutcomes of COVID-19 Patients Treated with Oral Anticoagulants." Angiology & Vascular Surgery 7, no. 2 (2022): 1–4. http://dx.doi.org/10.24966/avs-7397/100094.

Full text

Abstract:

Objective: We aimed to investigate the effects of warfar in and new-generation oral anticoagulants on the prognosis of patients diagnosed with Corona Virus Disease 2019 (COVID-19). Materials and Methods: Patients diagnosed with COVID-19 were divided into two groups depending on whether they were using warfarin or a new-generation oral anticoagulant. The types of chronic diseases, drugs used, haematological and biochemical parameters and prognoses in each group were statistically analysed. Results: Twenty-three patients (37.1%) using warfarin and 39 (62.9%) patients using new-generation oral an

APA, Harvard, Vancouver, ISO, and other styles

21

Ali Asgar, Juzer, Amal Benchakroun, Nicholas Sass, et al. "Comparing the Efficacy and Safety of Apixaban and Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease." Blood 144, Supplement 1 (2024): 5583. https://doi.org/10.1182/blood-2024-212201.

Full text

Abstract:

Introduction A key part of the management of atrial fibrillation is anticoagulation to reduce the risk of stroke1. Chronic kidney disease (CKD) is known to promote atrial fibrillation, possibly through an inflammatory pathway2. While anticoagulation for atrial fibrillation has traditionally been done with warfarin, a vitamin K antagonist, it can also be accomplished via a direct oral anticoagulant (DOAC), including the factor Xa inhibitor apixaban. Recent studies have shown that a DOAC is noninferior to warfarin3. However, most studies have excluded people with advanced CKD. This retrospective

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1376 (2011): 30. http://dx.doi.org/10.2165/00128415-201113760-00102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1377 (2011): 37–38. http://dx.doi.org/10.2165/00128415-201113770-00129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1377 (2011): 38. http://dx.doi.org/10.2165/00128415-201113770-00133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1377 (2011): 38. http://dx.doi.org/10.2165/00128415-201113770-00134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1379 (2011): 37. http://dx.doi.org/10.2165/00128415-201113790-00141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1382 (2011): 35. http://dx.doi.org/10.2165/00128415-201113820-00128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1382 (2011): 35. http://dx.doi.org/10.2165/00128415-201113820-00129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1383 (2012): 37. http://dx.doi.org/10.2165/00128415-201213830-00127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1385 (2012): 45–46. http://dx.doi.org/10.2165/00128415-201213850-00167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1390 (2012): 42. http://dx.doi.org/10.2165/00128415-201213900-00162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1391 (2012): 41–42. http://dx.doi.org/10.2165/00128415-201213910-00153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1391 (2012): 42. http://dx.doi.org/10.2165/00128415-201213910-00154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1392 (2012): 46. http://dx.doi.org/10.2165/00128415-201213920-00156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1393 (2012): 41. http://dx.doi.org/10.2165/00128415-201213930-00146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Warfarin." Reactions Weekly &NA;, no. 695 (1998): 12. http://dx.doi.org/10.2165/00128415-199806950-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Warfarin." Reactions Weekly &NA;, no. 709 (1998): 12. http://dx.doi.org/10.2165/00128415-199807090-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Warfarin." Reactions Weekly &NA;, no. 713 (1998): 12. http://dx.doi.org/10.2165/00128415-199807130-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Warfarin." Reactions Weekly &NA;, no. 717 (1998): 11–12. http://dx.doi.org/10.2165/00128415-199807170-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Warfarin." Reactions Weekly &NA;, no. 720 (1998): 12. http://dx.doi.org/10.2165/00128415-199807200-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Warfarin." Reactions Weekly &NA;, no. 742 (1999): 12. http://dx.doi.org/10.2165/00128415-199907420-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Warfarin." Reactions Weekly &NA;, no. 745 (1999): 12. http://dx.doi.org/10.2165/00128415-199907450-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1167 (2007): 26–27. http://dx.doi.org/10.2165/00128415-200711670-00079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1169 (2007): 27. http://dx.doi.org/10.2165/00128415-200711690-00074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1172 (2007): 27. http://dx.doi.org/10.2165/00128415-200711720-00084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Warfarin." Reactions Weekly &NA;, no. 1175 (2007): 27. http://dx.doi.org/10.2165/00128415-200711750-00092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mahaboob, Sirajudeen, G. N. K. Ganesh, K. P. Arun, and S. D. Rajendran. "Various Factors Influencing the Enantiomers of Warfarin Pharmacokinetics: A Systematic Review of Population Pharmacokinetics." Journal of Pharmacology and Pharmacotherapeutics, December 15, 2023. http://dx.doi.org/10.1177/0976500x231211401.

Full text

Abstract:

Warfarin is the most commonly prescribed anticoagulant medication. Warfarin’s pharmacokinetics (PK) in its enantiomeric form have been reported to be highly variable. Five population pharmacokinetic model studies for warfarin were identified in this systematic review. This review summarized these studies and reported on various factors affecting warfarin PK. Most studies reported a one-compartment model with first-order absorption and elimination for both S-warfarin and R-warfarin. Warfarin disposition has been reported to be influenced by various factors, including gender, age, genetic variat

APA, Harvard, Vancouver, ISO, and other styles

48

Kim, Jae Ha, Yun Kyung Park, Suk Jae Kim, et al. "Abstract TP406: Impact Of Warfarin Pharmacogenomics In The Time In Therapeutic Range In Korean Patients With Atrial Fibrillation." Stroke 44, suppl_1 (2013). http://dx.doi.org/10.1161/str.44.suppl_1.atp406.

Full text

Abstract:

Background: Warfain is highly effective for stroke prevention in patients with atrial fibrillation (AF), but also has narrow therapeutic window (usually INR 2-3). Even in clinical trials with selected, closely monitored patients, the times in therapeutic range (TTR) of those taking warfarin is less than two thirds. Single nucleotide polymorphisms in genes affecting warfarin metabolism (cytochrome-P450 2C9, CYP2C9) and response (vitamin-K epoxide reductase complex 1, VKORC1) have an important influence on warfarin therapy. Initial INR response to warfain was reportedly associated with genetic v

APA, Harvard, Vancouver, ISO, and other styles

49

Kim, Michael H., Gary Puckrein, Qiang Cai, and Liou Xu. "Abstract 9: The Relationship Between Patient Diversity and Warfarin Use in Atrial Fibrillation: A Ten-Year Perspective (2000-2010) on Cardiovascular Outcomes." Circulation: Cardiovascular Quality and Outcomes 6, suppl_1 (2013). http://dx.doi.org/10.1161/circoutcomes.6.suppl_1.a9.

Full text

Abstract:

Background: Anticoagulants are effective in stroke prevention in patients with atrial fibrillation (AF). Warfarin’s comparative effectiveness in AF Medicare beneficiaries by race/ethnicity and gender is not well described. Methods: Medicare claims data for years 2000-2010 were used to calculate: 1) AF per annum prevalence (N > 1.9 million); and 2) rates of new AF cases (first Medicare reimbursement for AF), hospitalization, and mortality. Three 20 % samples of AF beneficiaries for years 2000 (n=266K), 2005 (n=316K), and 2007 (n=311K) were used to calculate warfarin use and stroke (ischemic)

APA, Harvard, Vancouver, ISO, and other styles

50

Ji, Hannah, Matthew F. Gill, Evan W. Draper, et al. "Abstract 15632: Warfarin Dose Management Using Offline Deep Reinforcement Learning." Circulation 148, Suppl_1 (2023). http://dx.doi.org/10.1161/circ.148.suppl_1.15632.

Full text

Abstract:

Introduction: Warfarin is a commonly prescribed anticoagulant for treating atrial fibrillation, mechanical valves, and venous thromboembolism. Warfarin dose management remains challenging due to dosing variability between patients and warfarin’s narrow therapeutic window. Time in therapeutic range (TTR) is critical to warfarin’s safety and efficacy, but TTR typically remains low (40-50%) in community practices. Specialized anticoagulation clinics and protocolized approaches can increase TTR but have great administrative burdens and health care costs. Aim: To develop standardized optimal warfar

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!